AstraZeneca opens new development operations centre in Bengaluru

Published On 2019-06-01 09:35 GMT   |   Update On 2019-06-01 09:35 GMT

Bengaluru: Drug firm AstraZeneca Thursday said it has opened a new development operations centre in Bengaluru to support the expansion of its clinical research footprint in India.


"The development operations centre will employ over 30 clinical research experts that handle over 20 studies in 150 sites across India," AstraZeneca said in a statement.












This expansion will focus on managing studies in India to not only support the global clinical drug development, but also the local business with clinical data and evidence, it added.

"Because of the excellent skills of Indian clinical research experts and the improvement of regulations and approval timelines, we are pleased to expand our operations and continue to lead clinical research in India," AstraZeneca Development Operations (Site Management and Monitoring), Asia, Middle East & Africa (AMEA) Senior Regional Director Melissa Grady said.

The unit will support the development of AstraZeneca's medicines, hosting clinical trial experts focused on the company's core therapeutic areas - oncology, cardiovascular, renal and metabolism, as well as respiratory, the statement said.

Read Also: AstraZeneca shows cardiovascular safety for roxadustat in global Phase III trials








Headquartered at Cambridge UK, AstraZeneca plc is a British-Swedish multinational pharmaceutical and biopharmaceutical company.

Article Source : PTI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News